Los Angeles Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Los Angeles Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.2K	Sell	275 -7,230	-96%	-$368K	﹤0.01%	1850
2025 Q4	$424K	Sell	7,505 -11,709	-61%	-$569K	﹤0.01%	960
2025 Q3	$918K	Hold	19,214	–	–	﹤0.01%	727
2025 Q2	$606K	Hold	19,214	–	–	﹤0.01%	802
2025 Q1	$629K	Buy	19,214 +31	+0.2%	+$1.1K	﹤0.01%	696
2024 Q4	$694K	Sell	19,183 -850	-4%	-$29.9K	﹤0.01%	728
2024 Q3	$625K	Buy	+20,033	New	+$625K	﹤0.01%	800
2023 Q3	–	Sell	-24,105	Closed	-$725K	–	1234
2023 Q2	$725K	Buy	+24,105	New	+$843K	﹤0.01%	737
2021 Q3	–	Sell	-22,690	Closed	-$699K	–	1588
2021 Q2	$699K	Sell	22,690 -14,820	-40%	-$454K	﹤0.01%	1017
2021 Q1	$982K	Buy	37,510 +16,630	+80%	+$465K	﹤0.01%	903
2020 Q4	$525K	Buy	+20,880	New	+$449K	﹤0.01%	1187
2020 Q3	–	Sell	-10,956	Closed	-$260K	–	1519
2020 Q2	$260K	Buy	10,956 +635	+6%	+$14K	﹤0.01%	1331
2020 Q1	$186K	Sell	10,321 -6,255	-38%	-$131K	﹤0.01%	1194
2019 Q4	$393K	Hold	16,576	–	–	﹤0.01%	1071
2019 Q3	$456K	Hold	16,576	–	–	﹤0.01%	1013
2019 Q2	$548K	Buy	+16,576	New	+$568K	﹤0.01%	1014
2018 Q4	–	Sell	-21,091	Closed	-$1.06M	–	1376
2018 Q3	$1.06M	Buy	21,091 +380	+2%	+$18.8K	0.01%	848
2018 Q2	$1.24M	Sell	20,711 -6,280	-23%	-$325K	0.01%	833
2018 Q1	$1.24M	Buy	26,991 +125	+0.5%	+$5.22K	0.01%	767
2017 Q4	$1.07M	Buy	26,866 +13,805	+106%	+$546K	0.01%	841
2017 Q3	$522K	Buy	+13,061	New	+$565K	﹤0.01%	1002

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Los Angeles Capital Management's SUPN Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 96% in Q1 2026, selling an estimated $368K and leaving 275 shares worth $14.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1850.

Los Angeles Capital Management first reported a position in SUPN in Q3 2017 and has held it in 21 quarters since. The position peaked at $1.24M in Q2 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Los Angeles Capital Management held 275 shares of Supernus Pharmaceuticals worth $14.2K as of Q1 2026.
Los Angeles Capital Management sold 7,230 Supernus Pharmaceuticals shares in Q1 2026, an estimated $368K.
Supernus Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1850 holding.
Los Angeles Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2017 and has held it in 21 quarters since.
Los Angeles Capital Management's Supernus Pharmaceuticals position peaked at $1.24M in Q2 2018.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.